stockportfolio.pro
Edwards Lifesciences Corporation (EW)
Healthcare · Medical Devices · NYSE
Edwards Lifesciences Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.96B | $3.44B | $3.72B | $4.35B | $4.39B | $5.23B | $5.38B | $6.00B | $5.44B | $6.07B |
| Gross profit | $2.17B | $2.56B | $2.78B | $3.23B | $3.31B | $3.98B | $3.74B | $4.03B | $4.32B | $4.73B |
| Net income | $0 | $0 | $0 | $0 | $0 | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B |
| Net margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 28.7% | 28.3% | 23.4% | 76.7% | 17.7% |
Source: Edwards Lifesciences Corporation SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into EW stock?
At today's market cap of $50.41B, Edwards Lifesciences Corporation is priced for free-cash-flow growth of about 16.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.33B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 15.6%/yr over the last five fiscal years and revenue 6.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Edwards Lifesciences Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeEdwards Lifesciences Corporation financial history by metric
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation — frequently asked questions
What is Edwards Lifesciences Corporation's revenue?
Edwards Lifesciences Corporation (EW) reported revenue of $6.07B for fiscal year 2025, up 11.5% from the prior year, according to its SEC filings.
Is Edwards Lifesciences Corporation profitable?
Yes. EW earned net income of $1.07B in fiscal 2025, a net margin of 17.7%.
What is EW's P/E ratio?
Edwards Lifesciences Corporation trades at a price-to-earnings ratio of about 47.3 based on the latest data in our nightly-refreshed cache.
How fast is Edwards Lifesciences Corporation growing?
EW's revenue grew at roughly 6.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Edwards Lifesciences Corporation have?
As of fiscal year 2025, EW carried roughly $598.30M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Edwards Lifesciences Corporation's gross margin?
EW's gross margin was 78.0% in fiscal 2025 — gross profit of $4.73B on revenue of $6.07B.
What is Edwards Lifesciences Corporation's market cap?
Edwards Lifesciences Corporation (EW) has a market capitalization of about $50.41B, based on the latest data in our nightly-refreshed cache.
When does Edwards Lifesciences Corporation's fiscal year end?
EW's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into EW stock?
At today's market cap of $50.41B, Edwards Lifesciences Corporation is priced for free-cash-flow growth of about 16.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.33B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 15.6%/yr over the last five fiscal years and revenue 6.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Edwards Lifesciences Corporation's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.